Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Unknown | 1 |
Small molecule drug | 1 |
Oncolytic virus | 1 |
Biological products | 1 |
Target |
Mechanism CD3 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PREP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Jun 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Start Date18 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TriSb92 ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
CDNF (Herantis Pharma) | Amyotrophic Lateral Sclerosis More | Preclinical |
HUP-55 ( PREP ) | Parkinson Disease More | Preclinical |
aMUC1aCD3 coding virus(TILT) ( CD3 x MUC1 ) | Lung Cancer More | Preclinical |
MPV-1743 | Obesity More | Discontinued |